SCHEMBL1610013

SCHEMBL1610013

CCC[CH]c1ccccc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
ALDH1A1 P00352 2/20 0.48
ACHE P22303 2/20 0.39
RAB9A P51151 3/20 0.36
KDM4E B2RXH2 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C19 P33261 1/20 0.36
APOBEC3A P31941 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
MEN1 O00255 1/20 0.35
PABPC1 P11940 1/20 0.35
KMT2A Q03164 1/20 0.35
TTR P02766 1/20 0.33
TP53 P04637 1/20 0.33
CYP2D6 P10635 1/20 0.33
THPO P40225 1/20 0.33
HIF1A Q16665 1/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1611320 0.87 TSHR (0.45) TSHRALDH1A1ACHERAB9AKDM4E
SCHEMBL1610236 0.85 ALDH1A1 (0.43) TSHRALDH1A1ACHERAB9AKDM4E
SCHEMBL5012483 0.84 TSHR (0.38) TSHRALDH1A1ACHERAB9AKDM4E
SCHEMBL1610408 0.84 TSHR (0.42) TSHRALDH1A1CYP1A2CYP2C19TP53
SCHEMBL9303850 0.84 TSHR (0.42) TSHRALDH1A1CYP1A2CYP2C19TP53
SCHEMBL1610543 0.84 TSHR (0.42) TSHRALDH1A1CYP1A2CYP2C19TP53
SCHEMBL9245692 0.84 TSHR (0.42) TSHRALDH1A1CYP1A2CYP2C19TP53
SCHEMBL369840 0.83 TSHR (0.54) TSHRALDH1A1ACHERAB9AKDM4E
SCHEMBL1611497 0.83 TRPA1 (0.37) TSHRALDH1A1ACHECYP1A2CYP2D6
SCHEMBL5008803 0.82 TSHR (0.36) TSHRALDH1A1ACHERAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0543919-B1 USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES SEARLE & CO (US) 1996-04-10 EP claimed
EP-0543919-A1 USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. SEARLE & CO (US) 1993-06-02 EP claimed
WO-1992003131-A1 USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES G.D. SEARLE & CO. (US) 1992-03-05 WO claimed
EP-0234944-A1 Insecticidal N'-substituted-N-acyl-N'-alkylcarbonylhydrazines ROHM AND HAAS COMPANY (US) 1987-09-02 EP claimed
CN-113831487-A Aromatic carboxylate intermediate, preparation method thereof and application thereof in ester type polycarboxylate superplasticizer 江苏苏博特新材料股份有限公司 2021-12-24 CN disclosed
WO-2021107870-A1 ANTIMICROBIAL AGENT, COATING FORMULATION, COMPOSITE SURFACE COATING AND METHODS OF PREPARING THE SAME AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-06-03 WO disclosed
US-10451967-B2 Acid- and radical-generating agent and method for generating acid and radical FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2019-10-22 US disclosed
US-9802902-B2 Antifungal compound AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-10-31 US disclosed
US-20170037013-A1 ANTIFUNGAL COMPOUND AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-02-09 US disclosed
US-20160342084-A1 ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2016-11-24 US disclosed
US-9493424-B2 Antifungal compound AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-11-15 US disclosed
US-20150203454-A1 ANTIFUNGAL COMPOUND AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-07-23 US disclosed
EP-0401166-A2 Nitrogen-containing titanocenes and their use CIBA-GEIGY AG (CH) 1990-12-05 EP disclosed
US-4906764-A Process for producing phosphinylamino acid derivatives NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1990-03-06 US disclosed
EP-0338702-A1 Nonlinear optical materials NIPPON OIL CO. LTD. (JP) 1989-10-25 EP disclosed
US-4857427-A Recording medium NIPPON OIL COMPANY, LIMITED (JP) 1989-08-15 US disclosed
EP-0318893-A2 Titanocenes, their use and N-substituted fluoroanilines CIBA-GEIGY AG (CH) 1989-06-07 EP disclosed
EP-0292918-A1 Process for producing phosphinylamino acid derivatives NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1988-11-30 EP disclosed
EP-0232113-A2 Recording medium including a glutamate copolymer NIPPON OIL CO. LTD. (JP) 1987-08-12 EP disclosed
EP-0226429-A2 Optical filter comprising a glutamate copolymer and a method of making an optical filter comprising glutamate copolymer NIPPON OIL CO. LTD. (JP) 1987-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10451967-B2 Acid- and radical-generating agent and method for generating acid and radical CBR1, HAO2, CBR3 TSHR 648/4885ALDH1A1 151/4885ACHE 4671/4885
US-20160342084-A1 ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL CBR1, HAO2, CBR3 TSHR 648/4885ALDH1A1 151/4885ACHE 4671/4885
US-20150203454-A1 ANTIFUNGAL COMPOUND ERG28, DPM1, BAK1 TSHR 4379/4885ALDH1A1 3011/4885ACHE 4790/4885
US-20170037013-A1 ANTIFUNGAL COMPOUND ERG28, DPM1, BAK1 TSHR 4379/4885ALDH1A1 3011/4885ACHE 4790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.